Merit Medical Systems Inc. reported first‑quarter 2026 results on April 30 2026, posting revenue of $381.9 million and a non‑GAAP earnings per share of $0.94. The company’s revenue beat the lower end of analyst consensus at $377.5 million by $4.4 million, or 1.2%, while falling short of the higher estimate of $385.2 million by $3.3 million. The non‑GAAP EPS surpassed the consensus range of $0.84‑$0.85 by $0.10, a 12% lift that reflects disciplined cost management and a favorable product‑mix shift toward higher‑margin therapeutic devices.
The company achieved 3.7% organic, constant‑currency revenue growth, driven by robust demand in its cardiovascular and endoscopy segments. Non‑GAAP operating margin expanded to 19.7% from 19.3% in the same quarter a year earlier, marking the highest first‑quarter margin in company history. Management attributed the margin improvement to pricing power, efficient operating leverage, and a shift toward higher‑margin therapeutic products.
Merit reorganized its revenue reporting into two categories—Foundational (67% of sales) and Therapeutic (33% of sales)—in Q1 2026. The company’s CEO, Martha G. Aronson, noted that “We delivered 3.7% organic, constant‑currency revenue growth, excluding the impact of a strategic divestiture.” The CFO, Raul Parra, added that “First quarter net income was $56.7 million or $0.94 per share compared to $52.9 million or $0.86 per share in the prior year period.”
Headwinds included a $4.6 million tariff hit and a China volume‑based procurement policy that limited sales volume. Despite these challenges, the company’s margin expansion and earnings beat demonstrate resilience. Management reiterated its full‑year guidance, maintaining a constant‑currency revenue growth outlook of 6‑8% and a non‑GAAP EPS range of $4.01‑$4.15. The guidance signals confidence in sustained demand and operational efficiency, while the company’s acquisition of View Point Medical strengthens its oncology platform.
The results underscore Merit’s ability to grow revenue and profitability even amid tariff headwinds and macro‑economic uncertainty. The record non‑GAAP operating margin and EPS beat suggest that the company’s strategic focus on higher‑margin therapeutic products and disciplined cost control are paying off, positioning it well for the remainder of the year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.